Survodutide
Survodutide (GLP-1 / glucagon dual agonist)
An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Overview
Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The glucagon component adds energy expenditure and liver-directed effects to the appetite and glucose benefits of GLP-1. Phase 2 trials reported meaningful weight loss and improvement in liver disease. It is not yet approved.
Mechanism of action
Agonizes both GLP-1 and glucagon receptors, combining appetite suppression and improved glucose handling with increased energy expenditure and hepatic fat reduction.
Key studies & citations
- Human2024
A Phase 2 randomized trial of survodutide in MASH and fibrosis
48-week trial in 293 adults with biopsy-confirmed MASH: histologic improvement without worsening fibrosis in 47 to 62% on survodutide versus 14% on placebo.
New England Journal of Medicine - Human2024
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
46-week trial in 387 adults without diabetes: mean weight change of minus 14.9% at 4.8 mg weekly versus minus 2.8% on placebo; gastrointestinal adverse events were common.
The Lancet Diabetes and Endocrinology - Human2026
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
Phase 3 in 216 adults: 84% on survodutide 6 mg versus 24% on placebo achieved at least a 30% liver-fat reduction, with minus 12.2% versus minus 1.0% body weight at 48 weeks.
Nature Medicine
Frequently asked questions
How is survodutide different from tirzepatide?
Both are dual agonists, but survodutide targets GLP-1 and glucagon receptors, while tirzepatide targets GLP-1 and GIP. The glucagon component is being studied especially for liver fat.